Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5616798 | The Journal of Thoracic and Cardiovascular Surgery | 2016 | 10 Pages |
Abstract
The trial successfully met both primary and secondary objectives, demonstrating that same-day isolation and autologous CD133+ cell delivery with coronary artery bypass grafting is safe and feasible. The positive findings support a larger randomized, multicenter trial, with higher numbers of transplanted cells to demonstrate beneficial effects. The upcoming IMPACT-CABG II trial will evaluate higher cell doses and pharmacologic enhancement to determine whether these cells improve perfusion and myocardial function.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Nicolas MD, MSc, Samer MD, Richard MD, Louis-Mathieu MD, PhD, Shant PhD, Katherine RN, MN, Andrew M. MRCP, Eric MD, Shu-Hong MD, Bernd MD, Minh Quan MD, Ignacio MD, Ren-Ke MD, PhD, Denis Claude MD, Terrence M. MD, MSc,